Skip to content

Pharmacokinetics and effects of oral clonidine in children with suspected Growth Hormone deficiency

Pharmacokinetics and effects of oral clonidine in children with suspected Growth Hormone deficiency - Clonidine in children with suspected Growth Hormone Deficiency

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31430
Enrollment
40
Registered
2007-03-22
Start date
2007-05-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Deficiency

Interventions

None listed

Sponsors

Centre for Human Drug Research
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - Written informed consent from parents or legal guardian, in the case of a child aged 12 years or older written informed consent from both parents/legal guardian and the child; - Patients must be 0-17 years of age; - Patients must have an indication for a clonidine test to investigate a possible growth hormone deficiency, and this is to be decided by or under supervision of a staff paediatrician, paediatric endocrinologist or fellow

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
- Pharmacokinetics of clonidine following oral administration - Growth hormone response following oral administration of clonidine - Cortisol response following oral administration of clonidine - Sedation depth following clonidine oral administration, measured with modified Ramsay Sedation Scale - Hemodynamic and respiratory parameters (Blood Pressure, Heart Rate, Transcutaneous oxygen saturation) following oral administration of clonidine

Secondary

MeasureTime frame
- Basal ACTH - Heart rate variability - QTc times before and after clonidine administration.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)